C3: Pursuing Racial Justice in Healthcare Financing Custom Case Solution & Analysis

1. Evidence Brief: Case Extraction

Financial Metrics

• C3 manages approximately 750 million dollars in annual medical spend for its Medicaid population.
• The organization represents 18 Federally Qualified Health Centers (FQHCs) across Massachusetts.
• Member FQHCs typically operate on thin margins, often between 1 percent and 3 percent.
• Value-based payment models currently rely on historical spending, which often reflects under-investment in marginalized communities.
• Source: Case Section on Financial Structure and Exhibit 1.

Operational Facts

• C3 is the only FQHC-led Accountable Care Organization (ACO) in the state of Massachusetts.
• The patient population is predominantly low-income, with over 70 percent identifying as people of color.
• Primary care services are the central operational unit, supplemented by behavioral health and social service integration.
• The organization uses a shared savings model where savings against a benchmark are distributed back to health centers.
• Source: Case Section on Operational Model and Exhibit 2.

Stakeholder Positions

• Christina Severin, CEO: Proponent of a radical shift in financing to address systemic racism directly.
• FQHC CEOs: Supportive of equity but concerned about financial stability and the administrative burden of new reporting requirements.
• MassHealth (State Medicaid): Interested in cost containment and health outcomes but constrained by state budgetary cycles and federal oversight.
• C3 Board: Focused on balancing the social mission with the long-term solvency of the ACO.
• Source: Stakeholder Interviews and Board Meeting Minutes.

Information Gaps

• The specific actuarial formula for the proposed equity-adjusted benchmark is not detailed.
• Long-term impact data on how equity-based financing affects specific clinical outcomes (e.g., hypertension control) is absent.
• The exact percentage of MassHealth total budget allocated for the RJHF pilot is not specified.

2. Strategic Analysis

Core Strategic Question

• How can C3 transition from a traditional value-based payment model to an equity-indexed financing framework without jeopardizing the financial viability of its member health centers?

Structural Analysis

Applying the Jobs-to-be-Done framework reveals that for C3 patients, the job is not just receiving medical treatment, but achieving health stability in an environment of systemic disadvantage. Current financing models only pay for the treatment, ignoring the environmental inputs. A Value Chain analysis indicates that the primary bottleneck is the input phase: the historical under-funding of social determinants leads to higher downstream costs that the ACO is then penalized for under standard benchmarks.

Strategic Options

Preliminary Recommendation

C3 should pursue Equity-Adjusted Benchmarking. This approach addresses the structural root of the problem by redefining the financial baseline. It moves beyond rewarding efficiency to rewarding the correction of systemic neglect. This is the only option that aligns the financial incentives of the state with the mission-driven goals of the FQHCs.

3. Implementation Roadmap

Critical Path

• Month 1-2: Finalize the actuarial model for equity adjustment using ZIP code and race-ethnicity data.
• Month 3-4: Secure a formal pilot agreement with MassHealth leadership for the upcoming contract cycle.
• Month 5-6: Deploy data dashboards to member FQHCs to track equity-adjusted performance in real-time.
• Month 7-12: Execute the first cycle of funding distribution based on the new benchmark.

Key Constraints

• Data Integrity: The reliance on self-reported race and ethnicity data is a significant point of failure.
• Payer Alignment: MassHealth must agree to a model that may increase short-term spending for long-term equity gains.
• Administrative Capacity: Member FQHCs lack the overhead to manage complex new reporting requirements.

Risk-Adjusted Implementation Strategy

The implementation will use a phased rollout. Phase one will apply the equity adjustment to a subset of the population (e.g., patients with chronic conditions) to test the actuarial validity. If the model proves stable, it will expand to the full population in year two. This mitigates the risk of a catastrophic financial shortfall if the initial projections are inaccurate.

4. Executive Review and BLUF

BLUF (Bottom Line Up Front)

C3 must implement the Racial Justice in Healthcare Financing (RJHF) model immediately. Traditional value-based care models are structurally biased; they reward efficiency in systems that have historically under-served people of color, effectively baking-in racial disparities. By adjusting benchmarks to reflect the true cost of achieving equity, C3 can flip the incentive structure. The financial risk is manageable if the pilot is phased, but the mission risk of maintaining the status quo is terminal. The organization should prioritize negotiating the equity-adjusted benchmark with MassHealth as the primary vehicle for change. This is not a social program; it is a fundamental correction of a flawed financial product.

Dangerous Assumption

The analysis assumes that MassHealth possesses the political will and budgetary flexibility to sustain higher benchmark payments during economic downturns. If the state reverts to pure cost-containment, the RJHF model will be the first to be defunded.

Unaddressed Risks

• Adverse Selection: If C3 benchmarks are higher, other ACOs may attempt to shift high-cost, marginalized patients toward C3, overwhelming the system.
• Data Latency: Claims data typically lags by six months, making it difficult for FQHCs to adjust operations in time to meet annual equity targets.

Unconsidered Alternative

The team did not fully evaluate a pure Direct Contracting model with social service providers. Instead of FQHCs managing the social spend, C3 could have carved out a portion of the budget to pay community-based organizations directly, bypassing the clinical administrative layer entirely.

Verdict

APPROVED FOR LEADERSHIP REVIEW